CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
Year-over-year operating income growth rate
Percentile
P21
Within normal range
vs 5Y Ago
-99.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -77.14% |
| Q3 2025 | -1126.13% |
| Q2 2025 | -105.68% |
| Q1 2025 | 27.95% |
| Q4 2024 | 330.04% |
| Q3 2024 | 148.64% |
| Q2 2024 | -172.51% |
| Q1 2024 | 2023.60% |
| Q4 2023 | -105.46% |
| Q3 2023 | 431.33% |
| Q2 2023 | 40.77% |
| Q1 2023 | 40.54% |
| Q4 2022 | 68.00% |
| Q3 2022 | 1.14% |
| Q2 2022 | 6.26% |
| Q1 2022 | -21.87% |
| Q4 2021 | -16.20% |
| Q3 2021 | -17.89% |
| Q2 2021 | -22.90% |
| Q1 2021 | -5.74% |
| Q4 2020 | 0.78% |
| Q3 2020 | 7.70% |
| Q2 2020 | -477.80% |
| Q1 2020 | 92.53% |
| Q4 2019 | -45.34% |
| Q3 2019 | 17.66% |
| Q2 2019 | -88.55% |
| Q1 2019 | 35.82% |
| Q4 2018 | -11.36% |
| Q3 2018 | -74.83% |
| Q2 2018 | 15.18% |
| Q1 2018 | -1153.41% |
| Q4 2017 | 88.69% |
| Q3 2017 | 56.55% |
| Q2 2017 | -194.56% |
| Q1 2017 | 39.47% |
| Q4 2016 | 4.60% |
| Q3 2016 | -4.61% |
| Q2 2016 | 11.89% |
| Q1 2016 | -40.42% |